Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03118232
Other study ID # 20151805
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 3, 2017
Est. completion date October 10, 2023

Study information

Verified date December 2023
Source University of California, Irvine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a cluster-randomized trial of nursing homes to assess whether decolonization with routine chlorhexidine bathing and periodic use of nasal antiseptics can reduce hospitalizations associated with infections, antibiotic utilization, and multi-drug resistant organism (MDRO) prevalence. The comparator arm will be routine bathing care.


Recruitment information / eligibility

Status Completed
Enrollment 13952
Est. completion date October 10, 2023
Est. primary completion date October 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Nursing homes will be eligible to participate if they meet the following criteria: - Licensed nursing home in Orange County or Southern Los Angeles County serving adults - Minimal use of chlorhexidine bathing* - Minimal use of nasal decolonization* *Minimal use defined as <15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay. Exclusion Criteria Nursing homes will not be eligible to participate if they meet the following criteria: - Facilities routinely using decolonization - Dedicated psychiatric nursing homes - Facilities with a resident population with >=20% combative patients - Pediatric facilities Note: in any participating nursing home, residents with active end-of-life comfort care only measures are excluded

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chlorhexidine gluconate (CHG)
2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
Iodophor (10% povidone-iodine)
Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.

Locations

Country Name City State
United States Anaheim Crest Nursing Center Anaheim California
United States Buena Vista Care Center Anaheim California
United States Sun Mar Nursing Center Anaheim California
United States Walnut Village Rehabilitation and Care Center Anaheim California
United States West Anaheim Extended Care Anaheim California
United States Bel Tooren Villa Convalescent Hospital Bellflower California
United States Capistrano Beach Care Center Capistrano Beach California
United States Downey Care Center Downey California
United States Gordon Lane Care Center Fullerton California
United States Terrace View Care Center Fullerton California
United States Windsor Gardens Care Center of Fullerton Fullerton California
United States Pacific Haven Subacute Healthcare Center Garden Grove California
United States Las Flores Convalescent Hospital Gardena California
United States Park Regency Care Center La Habra California
United States Bixby Knolls Healthcare Center Long Beach California
United States Intercommunity Care Center Long Beach California
United States Pacific Villa Inc. Long Beach California
United States Regency Oaks Post Acute Care Center Long Beach California
United States Vista Cove Care Center at Long Beach Long Beach California
United States Windsor Convalescent of North Long Beach Long Beach California
United States Royal Oaks Care Center Lynwood California
United States Norwalk Skilled Nursing and Wellness Center Norwalk California
United States Villa Elena Care Center Norwalk California
United States Del Amo Gardens Care Center Torrance California
United States Harbor Post-Acute Care Center Torrance California
United States Heritage Rehabilitation Center Torrance California
United States Sunnyside Nursing Center Torrance California
United States Torrance Care Center West Torrance California

Sponsors (4)

Lead Sponsor Collaborator
University of California, Irvine Agency for Healthcare Research and Quality (AHRQ), Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, University of Massachusetts, Amherst

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript) Probability of colonization with any multidrug-resistant organism (MDRO): (MRSA, VRE, ESBL, CRE) Once in baseline and once at end-intervention (month 15-18 of intervention period)
Other Hospital Transfers Due to Infection in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017) Probability that a transfer to a hospital is due to an infection for long stay and short stay resident subsets 18 months
Other All Hospital Transfers in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017) Probability that a discharge is to a hospital for long stay and short stay resident subsets 18 months
Other Emergency Department Transfers Due to Infection (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017) Probability that a resident is sent to the emergency department for an infection, overall for long stay and short stay resident subsets 18 months
Primary Hospital Transfers Due to Infection Probability that a transfer to a hospital is due to an infection 18 months
Secondary All Hospital Transfers Probability that a discharge is to a hospital 18 months
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A